IgM monoclonal gammopathy of undetermined significance (MGUS) is defined by asymptomatic circulating IgM monoclonal protein below 30 g/L with a lymphoplasmacytic bone marrow infiltration of less than 10%. A significant proportion, however, develop unique immunological and biochemical manifestations related to the monoclonal protein itself in the absence of overt malignancy and are termed IgM-related disorders or, more recently, monoclonal gammopathy of clinical significance. The indication for treatment in affected patients is dictated by the pathological characteristics of the circulating IgM rather than the tumor itself. The clinical workup and treatment options vary widely and differ from those for Waldenström macroglobulinemia. The aim of this review is to alert clinicians to IgM monoclonal gammopathy of clinical significance and to provide practical guidance on when to screen for these phenotypes. We discuss clinical characteristics, the underlying clonal profile, diagnostic workup and treatment considerations for five important subtypes: cold agglutinin disease, type I and II cryoglobulinemia, IgM-associated peripheral neuropathy, Schnitzler syndrome and IgM-associated AL amyloidosis. The inhibition of the pathogenic effects of the IgM has led to great success in cold agglutinin disease and Schnitzler syndrome, whereas the other treatments are centered on eradicating the underlying clone. Treatment approaches in cryoglobulinemia and IgM-associated peripheral neuropathy are the least well developed. A multidisciplinary approach is required, particularly for IgM-related neuropathies and Schnitzler syndrome. Future work exploring novel, clone-directed agents and pathogenic IgM-directed therapies is welcomed.
commonly arises from a CD20+ lymphoplasmacytic cell without class-switching. The risk of progression to lymphoma, chronic lymphocytic leukemia, AL amyloidosis or multiple myeloma is 1.1 event per 100 person-years. In the largest series of 210 patients with IgM MGUS with a median follow-up of 29.3 months, no patients progressed to IgM myeloma. The incidence and prevalence of IgM MGCS are unknown. Clonal B cells in MGUS have the same genetic and molecular signature as the WM clone. However, MGUS cases have a significantly lower number of mutations than in WM, indicating multiple genetic hits are required for progression. The somatic \( \text{MYD88L265P} \) mutation constitutively activates nuclear factor \( \kappa B \) and triggers B-cell proliferation. It is considered an early acquired mutation and is present in the majority of patients with WM or IgM MGUS. The gene encoding the chemokine receptor \( \text{CXCR4} \), involved in homing of B cells in the bone marrow, is mutated (\( \text{CXCR4MUT} \)) in a smaller proportion. This is usually a subclonal mutation and likely a late event. IgM myeloma has a distinct cell of origin, a pro-B cell, with frequent t(11;14), an absence of \( \text{MYD88L265P} \) mutation and high BCL2/BCL2L1 ratio. These clonal characteristics may have therapeutic implications. Table 2 summarizes the data on the underlying histology and clonal characteristics of IgM MGCS compared with those seen in WM and IgM MGUS in general.

**Primary cold agglutinin disease**

In primary CAD, autoimmune hemolytic anemia is caused by a cold agglutinin that is a monoclonal IgM in more than 90% of cases and is produced by clonal lymphocytes in the bone marrow. The antibody binds erythrocyte antigens (typically type I) optimally at 4°C resulting in agglutination and classical complement pathway activation. The thermal amplitude describes the temperature range at which the antibodies are active, and only those with a thermal amplitude reaching higher than 28°C are considered pathogenic. In most cases, complement activation is incomplete and extravascular hemolysis of C3b-opsonized erythrocytes occurs in the liver. Less frequently there is initiation of the terminal pathway, assembly of the membrane attack complex (C5b-C9) and intravascular hemolysis, which can lead to acute life-threatening anemia. Cold agglutinins in the context of infection, autoimmune disease and overt lymphoma (including chronic lymphocytic lymphoma, diffuse large B-cell lymphoma and WM) are referred to as cold agglutinin syndrome. The management of cold agglutinin syndrome is directed at treating the underlying cause and is not further discussed here.

**Clinical characteristics**

Patients with CAD present with chronic anemia and/or cold-induced circulatory symptoms. Of 232 patients in an international retrospective case series, the median IgM was 3.2 g/L and over 90% had hemolytic anemia and circulatory symptoms. Thirty-eight percent required transfusions at or before diagnosis and 47% during follow-up. Around half had acrocyanosis or Raynaud syndrome affecting daily living. Ulcers or gangrene were rare (<2%). In a third of cases, hemoglobin concentration is below 80g/L. Circulatory symptoms do not correlate with either the degree of anemia or the bone marrow histology. There is an increased risk of thrombosis in CAD, likely related to intravascular hemolysis, which is not correlated with the severity of the anemia. CAD is a chronic disease.
Table 2. Clonal characteristics of IgM monoclonal gammopathies of clinical significance, monoclonal gammopathies of undetermined significance and Waldéström macroglobulinemia.

|                          | IgM MGUS | WM | Cold agglutinin disease | Cryoglobulinemia | IgM AL amyloidosis | Anti-MAG neuropathy | Schnitzler syndrome |
|--------------------------|-----------|----|-------------------------|-----------------|-------------------|---------------------|--------------------|
| **Histology, %**         |           |    |                         |                 |                   |                     |                    |
| MGUS (<10% infiltration) | 100       | 0  | 0                       | 70              | 27                | 60                  | 73                 |
| WM (>10% infiltration)   | 0         | 100| 71                      | 30              | 54                | 35                  | 13                 |
| Other                    |           |    | 24                      | 20              | 19                | 8                   | 15                 |
| **IgM light chain restriction, %** |     |    |                          |                 |                   |                     |                   |
| IgMk 70                  |           |    |                         |                 |                   |                     |                    |
| IgMk 75                  |           |    |                         |                 |                   |                     |                    |
| IgMv 100                 |           |    |                         |                 |                   |                     |                    |
| IgMk 85                  |           |    |                         |                 |                   |                     |                    |
| **Molecular studies in bone marrow, %** |     |    |                          |                 |                   |                     |                    |
| MYD88L265P               | Up to 80  | 0  | 5                       | Not reported    | 58                | 73                  | Not reported**     |
| CXCR4MUT                 | >90       | 40 | 40                      | Not reported**  | 17**              | 12**                | Not reported**     |
| IGHV/IGLGV gene usage    | VH3       |    | VH3                     | VH4-34          | LV2               | VH4-34              | VH3                |

*MYD88L265P reported in 92% of WM associated type I cryoglobulinemia; **These mutations are not seen in the pure plasma cell neoplasm subtype. ***30% in peripheral blood. MGUS: monoclonal gammopathies of undetermined significance; WM: Waldéström macroglobulinemia; MAG: myelin-associated glycoprotein.

and affected patients have an estimated 16-year survival. Clonality has been demonstrated in approximately 80% of cases and the remainder likely require more sensitive methods to detect the pathogenic clone. The CAD clone has a distinct phenotype that differs from that of WM. MYD88L265P is rarely seen. Recurrent somatic mutations in CXCR4 (20%), KMT2D (69%) and CARD11 (31%) have been described. Recurrent chromosomal abnormalities have been identified. Based on bone marrow biopsies of 54 cases of CAD, the entity "CAD-associated lymphoproliferative disorder" has been defined, with typical morphology including absent plasmacytoid cells, universally restricted IGHV4-34 gene usage and lack of MYD88L265P. Most patients meet the criteria for MGUS and extramedullary disease is rare.

**Diagnostic workup**

Laboratory findings are consistent with hemolysis (and may, therefore, include reticulocytosis, elevated lactate dehydrogenase, unconjugated hyperbilirubinemia and decreased haptoglobin), the monospecific direct antiglobulin test is strongly positive for C3d and there is a cold agglutinin titer of ≥1:64 at 4°C. Blood samples should be handled warm until separation to prevent agglutination.

**Treatment**

Treatment goals are to alleviate cold-induced symptoms and hemolytic anemia. Response assessment should evaluate hemolytic activity and symptoms as well as clonal response. There are no standard criteria to assess response of cold-induced peripheral symptoms and instead clinicians depend on patient-reported outcomes. A treatment algorithm is provided in Figure 1 and Online Supplementary Table S1. All patients should avoid exposure to cold and be observed, particularly during periods of febrile illness and surgery. Red blood cells should be transfused via a blood warmer. Symptomatic patients should commence use of folic acid and be considered for thromboprophylaxis. It is important to note that steroids and splenectomy are not effective in CAD.

We recommend a frontline clone-directed approach (Figure 1), although achieving complete eradication is rare. The most established treatment is rituximab-based therapy. Prospective trials of rituximab monotherapy show a modest response rate of 50% with rare complete responses. Real-world data show a 15-month median response duration and repeated responses in over a third of patients. Efficacy is greatly improved by the addition of bendamustine. In a prospective study of the bendamustine-rituximab combination with a reduced dose of 70 mg/m² bendamustine delivered for four cycles to 45 patients, the response rate was 71%, with 40% complete responses and a median increase of hemoglobin of 44 g/L. Grade 4 neutropenia was observed in 20% of the patients and 29% required a dose reduction. According to updated data, both the overall and complete response rates improved due to deeper responses over time.
bine is efficacious (response rate: 62%; complete responses: 38%) but associated with an increased risk of secondary malignancy and is therefore not a preferred option. Based on a prospective study of 19 patients, the response rate to bortezomib-based treatment was 32%, although this was after only a single course of bortezomib. Bruton tyrosine kinase (BTK) inhibitors were effective in all four treated patients with relapsed CAD in a retrospective report. There is a case report of the use of daratumumab in CAD. Clinical trials should be considered in relapsed disease. Promising studies have examined proximal complement inhibition to inhibit extravascular hemolysis. Complement inhibition necessitates indefinite treatment and fails to reduce vascular symptoms. In a phase III study of anti-C1s, sutimlimab, versus best supportive care, it was seen that the complement inhibitor rapidly halted hemolysis, produced transfusion independence in 73% of patients, increased hemoglobin concentration by more than 15 g/L and improved fatigue; this drug has now been approved by the Food and Drug Administration. The effect of complement inhibition on thrombosis has not been established; however, D-dimer and thrombin-antithrombin complex levels decreased on treatment. Use of the C5 inhibitor eculizumab rapidly abrogates the terminal complement pathway with a short time to response. However, in a phase II trial there was a marginal hemoglobin rise of 8 g/L. Proximal complement inhibition presumably has greater effectiveness because it targets C3-mediated hemolysis via the liver, which is often predominant in CAD. Ongoing clinical trials of complement inhibition in CAD include those studying the C3b inhibitor, pegcetacoplan (phase III, NCT05096403), the complement factor B inhibitor, iptacopan (phase II, NCT05086744), the C1 esterase inhibitor, cinryze (phase II, 2012-003710-13/NL) and the C1s inhibitor BIVV020 (phase Ib, NCT04269551). Acute life-threatening intravascular hemolysis may necessitate transfusion. Plasma exchange may be employed provided that all priming fluids and the circuit apparatus are pre-warmed and that the replacement products are run through a warmer. Erythropoietin support can be considered as erythropoietin can be inappropriately low in autoimmune hemolytic anemia. Complement-directed therapy may act as a bridge for rituximab combinations to target the underlying clone, which can take weeks to have an effect.

**Cryoglobulinemia**

Cryoglobulinemia is characterized by immunoglobulins that precipitate at temperatures below 37°C and redissolve on warming. Monoclonal IgM can be associated with type I and type II cryoglobulinemia. Type I cryoglobulinemia consists of monoclonal immunoglobulins only. In type II “mixed” cryoglobulinemia there is a monoclonal com-
ponent possessing avidity for the polyclonal component of a different isotype (most frequently IgM with rheumatoid factor activity, the ability to bind to the Fc portion of IgG). The rheumatoid factor detected in type II cryoglobulinemia is a monoclonal IgMk in over 85% of cases. While most cases of type II cryoglobulinemia are related to hepatitis C, here we focus on those related to monoclonal IgM.

Clinical characteristics

Data characterizing patients with monoclonal IgM and cryoglobulinemia are scant. The clinical characteristics have been gleaned from retrospective cohorts grouping together IgG and IgM cases. The largest series reported over 1,600 unselected patients with cryoglobulinemia. Nine percent had type I cryoglobulinemia and 47% had type II. The only series characterizing the symptoms of IgM type I cryoglobulinemia included 26 patients; 35% had underlying MGUS, 35% had WM and 31% had non-Hodgkin lymphoma. The incidence is likely underestimated if the clinical suspicion is high. Increased plasma viscosity in the absence of a high IgM should trigger clinicians to consider cryoglobulinemia. A tissue biopsy may be indicated to identify renal or nerve involvement and distinguish it from other causes. Intravascular precipitation of IgM triggered by exposure to cold results in thrombotic obstruction and ischemia in small vessels as evidenced on biopsy in type I cryoglobulinemia. Leukocytoclastic vasculitis may be evident in type II cryoglobulinemia.

Treatment

A treatment approach is outlined in Figure 2. There is a paucity of data to guide optimal management. Mild symptoms may abate with cold prevention. Rapidly progressive nephropathy and neuropathy have been reported at various stages of the disease course, so careful monitoring is recommended. When cryoglobulinemia is tested for exclusively in symptomatic patients, treatment is commenced for cryoglobulinemia-related symptoms in the majority (80%). Response assessment is not standardized and mostly focuses on symptomatic improvement. The cryocrit at treatment initiation, change in cryocrit and time to nadir were predictive of symptom improvement in a mixed cohort of patients with IgG and IgM type I cryoglobulinemia. The underlying diagnosis of MGUS or lymphoma did not affect symptom improvement. Treatment regimens are heterogeneous and have been used in small series of patients. Plasma exchange may temporize critical symptoms and is used in up to a third of all cases of cryoglobulinemia in mixed cohorts; a warming procedure should be in place. In the absence of robust evidence, definitive treatment should be directed at the underlying clone. Steroids (1 mg/kg) are used in up to 90% of all cases of cryoglobulinemia, often together with immunosuppression. Rituximab combinations or bortezomib-based treatment are typically employed with symptomatic responses in approximately 80% of cases. Disappearance of cryoglobulin may be seen in half of patients. Transient disease exacerbation (an ‘IgM flare’) has been described following the use of rituximab in type I cryoglobulinemia with a low disease burden (<10% infiltrate) and in type II cryoglobulinemia.

Diagnostic workup

Laboratory testing is critical as a minimal amount of measurable cryoglobulin may cause symptoms. In one study in which two-thirds of patients were symptomatic, 58% of the IgM type I cryoglobulinemia cases had a cryocrit of <1%, which was a significantly greater proportion than in IgG cryoglobulinemia. Symptoms do not correlate with the cryocrit and depend instead on the temperature at which precipitation occurs. Accurate detection of cryoglobulins requires samples to be taken into prewarmed tubes which must not be allowed to cool below 37°C until the serum is separated, as the cryoglobulin may precipitate and not be detected. Similarly, a false-negative M-protein result may result from the same process. In a French study, 9% of cases with negative results were positive on a follow-up test. Care must be taken with pre-analytical variables; repeat testing of M-protein and cryoglobulins is indicated if the clinical suspicion is high. Increased plasma viscosity in the absence of a high IgM should trigger clinicians to consider cryoglobulinemia. A tissue biopsy may be indicated to identify renal or nerve involvement and distinguish it from other causes. Intravascular precipitation of IgM triggered by exposure to cold results in thrombotic obstruction and ischemia in small vessels as evidenced on biopsy in type I cryoglobulinemia. Leukocytoclastic vasculitis may be evident in type II cryoglobulinemia.
authors have suggested that a post-rituximab flare in type II cryoglobulinemia may be due to the exogenous IgG from the rituximab infusion which may also be a target of the monoclonal IgM. A study examining plasma exchange prior to rituximab to prevent IgM flares is ongoing (NCT04692363). Currently there are no data on the use of autologous stem cell transplantation or BTK inhibitors in IgM-associated cryoglobulinemia.

IgM-associated AL amyloidosis

AL amyloidosis is a rare disorder caused by extracellular deposition of insoluble misfolded monoclonal light chain fragments, produced by an underlying plasma cell dyscrasia or lymphoma, as amyloid fibrils in tissues. IgM-associated amyloidosis accounts for 5 to 7% of all systemic amyloidoses. In non-IgM AL amyloidosis, advances in treatment have resulted in marked improvement in survival, although patients with advanced disease have a poor outcome. Data on IgM-associated AL amyloidosis show no improvement over time.

Clinical characteristics

Due to its rarity, IgM-associated amyloidosis is less well characterized but increasingly recognized as a distinctive entity. When compared to non-IgM amyloidosis, patients are older with a history of MGUS or WM up to 65 months prior to diagnosis. Multiple series indicate a smaller proportion of λ light chain involvement compared to that in non-IgM cases. Presenting free light chain levels are lower than in non-IgM AL amyloidosis and in the largest study so far of IgM-associated amyloidosis only two-thirds of the 250 patients had a greater than 50 mg/L difference between involved and uninvolved free light chains. The pattern of organ involvement is also different, with a greater propensity for lymph node and soft tissue deposition (35%). Cardiac involvement is less common (45%) and neuropathy more frequent (28%).

Diagnostic workup

The exact nature of the clonal dyscrasia in IgM-associated AL amyloidosis remains unclear. The Mayo group has suggested two types, based on morphology; lymphoid predominant (lymphoplasmacytic lymphoma) or plasma cell predominant (pure plasma cell neoplasm). Of 75 cases, the lymphoid predominant type (63%) showed a higher tumor infiltrate, MYD88L265P in 84%, CXCR4MUT in 29% but absent t(11;14), similar to WM. By contrast, the cases of pure plasma cell neoplasm (23%) had similar rates of t(11;14) compared to non-IgM-associated amyloidosis and no MYD88L265P/CXCR4MUT, similar to IgM myeloma. Patients with the pure plasma cell neoplasm type appear to have
poorer outcomes. These findings need independent confirmation to hone treatment approaches.

**Treatment**

There are no consensus guidelines, approved treatments or prospective clinical trials for IgM amyloidosis. The aims of treatment are to reduce the clonal burden and improve performance status with a view to extending survival. A treatment algorithm is summarized in Figure 3. Evidence is largely limited to retrospective series with heterogeneous regimens. Criteria developed for response assessment in non-IgM AL amyloidosis are applicable to IgM-associated AL amyloidosis with assessment of hematologic response and organ response. Response assessment by both free light chains and M-protein had prognostic significance in retrospective series alongside age, Mayo stage, cardiac involvement, liver involvement and prior WM treatment. β₂-microglobulin and lactate dehydrogenase levels do not independently affect survival, unlike in WM, which may be related to the low tumor burden. Despite less cardiac involvement, patients with IgM-associated amyloidosis do not have superior survival compared to those with non-IgM-associated amyloidosis, attributable to the inability to achieve deep clonal responses. Induction of hematologic response is more challenging with a reported 6-month overall response rate of 39% versus 59% (P=0.008), deep responses are seen in only 24%. Organ response rates are consequently poor (5% cardiac, 18% renal) and lower than those in a non-IgM-associated cohort. However, up to just 25% of all-comers were eligible for this intense therapy. The largest series of autologous stem cell transplantation in 38 patients included 58% who had received prior therapy and the 100-day mortality was 5%. There was, however, a relatively low rate of cardiac involvement (26%), demonstrating the importance of the selection of patients. Induction chemotherapy prior to autologous stem cell transplantation is not universally utilized. Conditioning most commonly involves melphalan, however the BEAM (carmustine, etoposide, cytarabine, melphalan) regimen has also been used. As the majority of cases have an underlying lymphoplasmacytic clone, induction therapy with rituximab-based combination chemotherapy is strongly preferred. In 27 cases, the bendamustine-rituximab combination resulted in an intention-to-treat hematologic response rate of 59%, with complete responses in 11%, and a median progression-free survival of 34 months. Sixty percent of patients treated with this combination in second line achieved a very good partial response. Bendamustine is neither neurotoxic nor cardiotoxic. Bortezomib in combination with

---

**Figure 3. Management of IgM-associated amyloidosis.** *Histological assessment includes targeting affecting organ, consider abdominal fat biopsy. Exclude other acquired and hereditary amyloidoses. **Organ assessment includes comprehensive evaluation of organs including cardiac, renal, neurological, gastrointestinal and soft tissue involvement. M-protein: monoclonal protein; SPEP: serum protein electrophoresis; SFLC: serum free light chains; LPL: lymphoplasmacytic lymphoma; CT: computed tomography; PET: positron emission tomography; MRI: magnetic resonance imaging; PPCN: pure plasma cell neoplasm; R-Bendamustine: rituximab plus bendamustine; BEAM: carmustine, etoposide, cytarabine, melphalan; Mel, melphalan; ASCT: autologous stem cell transplantation; AL: AL amyloidosis.*

---
rituximab and dexamethasone may provide rapid disease control. The only prospective trial of this strategy recruited ten patients over 1 year.46 A hematologic response was achieved by 78% with sustained responses at a median of 11 months, after only two cycles. However, there were no complete responses. Treatment had to be interrupted in 30% of patients because of toxicity. Patients with grade 3 sensory and/or grade 1 painful neuropathy were excluded and treatment-related neuropathy is a particular concern in these patients. Responses to frontline alkylating agents have been disappointing. In a series of 46 patients treated after 2003, the hematologic response rate was 37% and there were no complete responses.41 Immunomodulatory drugs alone result in variable response rates, but mostly less than 50%. BTK inhibitors, although promising in WM, have been associated with low response rates in IgM-associated amyloidosis. Of eight patients treated with ibrutinib, only two achieved a hematologic response and the median overall survival was 9 months.47 No studies have examined anti-CD38-bortezomib combinations, which is the standard of care in non-IgM AL amyloidosis.48 We consider upfront bendamustine-rituximab the treatment of choice in IgM-associated amyloidosis, consoli-
dated with autologous stem cell transplantation when the patient’s performance status allows. There is no consensus regarding less fit patients; treatment choices need to be individualized depending on affected organs and tolerance of treatments. Overall in this condition, deep responses remain poor. Future studies are required to address whether regimens based on novel agents (including venetoclax, daratumumab and the newer BTK inhibitors) may lead to improvements in the outcomes of patients with non-IgM AL amyloidosis.

IgM-related neuropathies

IgM-related peripheral neuropathies encompass an array of entities including immune-mediated neuronal damage, such as that caused by antibodies to myelin-associated glycoprotein (MAG), or direct neurotoxicity with infiltration by lymphoma (neurolymphomatosis), light chains (amyloi-
dosis) or cryoglobulins. Peripheral neuropathy has been found to occur in 15–30% of MGUS and WM cases,49,50 but the prevalence is likely affected by selection bias and vari-
able neurological evaluation in patients as part of a work-
up of IgM M-protein. The UK registry documented 153 patients with IgM-related neuropathy, comprising anti-
MAG neuropathy (55%), non-MAG IgM neuropathy (35%) and less frequently (<4% each) AL amyloidosis, cryoglobu-
linemia, anti-ganglioside neuropathy and CANOMAD syndrome (chronic ataxic neuropathy, ophthalmoplegia, IgM M-protein, cold agglutinins and disialosyl ganglioside antibodies).50

Clinical characteristics

Anti-MAG neuropathy is the most common and best-de-
dined IgM-related neuropathy. Patients typically present with chronic-onset, distal, symmetric neuropathy, sen-
sory ataxia and tremor. Patients may be misdiagnosed as
having chronic inflammatory demyelinating polyneu-
opathy. It is important to correctly classify the neuro-
pathy (Table 3) as this has significant management implications. Atypical “red flag” symptoms not consistent
with anti-MAG peripheral neuropathies include acute onset, rapid tempo of symptoms, pain, dysautonomia, weight loss, and cutaneous or central nervous system signs. These should alert the clinician to consider alternate diagnoses (Figure 4). CANOMAD syndrome is a very rare chronic progressive condition associated with anti-
ganglioside antibodies. This syndrome should be con-
sidered if there is sensory loss with ophthalmoplegia or ataxia. Bing-Neel syndrome is the term for central nerv-
ous system infiltration by lymphoplasmacytic lymphoma;
consensus guidelines on its diagnosis, treatment and re-
response criteria have been published.51 Cryoglobulinemia and amyloidosis are discussed in their respective sections.

Diagnostic workup

The majority of patients with IgM-related neuropathy (>90%) have symptoms of the underlying neurological dis-
order at diagnosis.50 This supports the strong need for
careful early evaluation of patients jointly with an expert
neurologist. The presence of a peripheral neuropathy
alongside a serum monoclonal IgM or anti-MAG antibody
does not equal a causal relationship, since gammopathies
as well as peripheral neuropathies are both increasingly
prevalent with age. Patients should be tested for anti-MAG antibodies, but only high-titer antibodies are clinically rel-
evant in the presence of a characteristic clinical picture
in anti-MAG neuropathy.52 A reduction in anti-MAG titers
and levels of IgM M-protein with therapy appeared to cor-
relate with improvement in neuropathy in a retrospective
analysis of 50 studies.53 Responders also had a younger age of onset.53

Nerve conduction tests and electromyography are war-
ranted and characteristically show demyelination with re-
duced conduction velocity, disproportionately prolonged
distal motor latency and absent sural potentials. Partial
motor conduction block is rare. Progressive demyelination
may result in secondary axonal loss which affects the like-
lihood of neural recovery.54 Magnetic resonance imaging of
the neuraxis and evaluation of large volumes of cerebro-
spinal fluid may be required if central nervous system in-
volve ment is suspected. A nerve biopsy may be needed if
the diagnosis remains elusive despite systematic investi-
gation. Comprehensive consensus guidelines provide
further details.52
| Feature                                      | Non-IgM-related | IgM-related |
|----------------------------------------------|-----------------|-------------|
| **CIDP**                                    | Gradually pro-  | Gradually   |
| Onset                                       | gressive, relap- | progressive |
| sing remitting                              |                |             |
| Treatment related                           | Treatment-      | Rapidly    |
| emergent                                    | progressive     | progressive |
| Anti MAG                                    | Symmetrical,    | Symmetrical,
| proximal, sensory and motor                 | distal, senso-  | distal, senso-
| rory predominant, mild-moderate             | ry predominant, | ry predominant,
| distal muscle weakness                      | mild-moderate   | mild-moderate |
| Demyelinating/axonal                        | Demyelinating   | Axonal      |
| Supportive tests                            | Conduction      | Mixed       |
| block and abnormal temporal dispersion       | block typical   | Axonal      |
| Timing is key. Most commonly bortezomib     | High anti-MAG   | Mixed       |
| Anti-MAG titer typical                      | negative        | Neither     |
| Clinical features are key (see CG section)  |                 |             |
| Organ involvement                           | Anti-ganglioside|             |
| Light chain predominance                    | Not IgM         | IgMκ 85%    |
| associated                                  | associated      | type I      |
| Light chain predominance                    | Not reported    | Not reported|
| Light chain predominance                    | IgMκ 70%-80%77  | in IgM. Overall λ LC restriction in POEMS |
| Light chain predominant                     | IgMκ, type I    | IgMλ, predominate |
| Light chain predominant                     |                 | No κ/λ      |
| Light chain predominance                    |                 | predominance |
| Light chain predominance                    |                 | IgMκ 84%61  |

*Red flag features. CIDP: chronic inflammatory demyelinating polyneuropathy; MAG: myelin-associated glycoprotein; PN: polyneuropathies; POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities; CANOMAD: chronic ataxic neuropathy, ophthalmoplegia, IgM M-protein, cold agglutinins and disialosyl ganglioside antibodies; CG: cryoglobulinemia; LC: light chain; CNS: central nervous system; CSF: cerebrospinal fluid; MRI: magnetic resonance imaging.
Treatment

In general, in anti-MAG and non-anti-MAG neuropathy, treatment should be initiated only in those with significant or progressive disability.52 The aim of treatment is to halt progression and improve neurological function, although this may potentially take months to years, even after IgM responses. Although many neurological disability scales exist, they are not available outside of specialist neurology clinics and there is no standardized method of response assessment. The use of serial validated patient-reported outcome scores (e.g., the Inflammatory Rasch-Built Overall Disability Scale) is advocated, as this can be easily undertaken in non-specialist clinics.53 An observational trial is currently recruiting with an aim to develop an IgM-specific disability scale (NCT03918421). Patients should be managed in a multidisciplinary fashion with input from neurology, hematology, physiotherapy and occupational therapy. Rituximab is widely, but inconsistently used in the setting of IgM-related neuropathies. A meta-analysis of rituximab demonstrated improvement in disability scales at 8 to 12 months and long-term efficacy was demonstrated in a third of patients.54 A transient flare of symptoms following the administration of rituximab was observed in 12% in a large series of patients with anti-MAG antibodies.55 Steroids, intravenous immunoglobulins and plasma exchange alone do not provide long-term clinical benefit in anti-MAG neuropathy56,57 and are resource-intensive, respectively. In contrast, intravenous immunoglobulins and rituximab-based regimens are effective in CANOMAD syndrome (producing partial clinical responses or better in 53% and 52% of patients, respectively),58 while chronic inflammatory demyelinating polyneuropathy is responsive to intravenous immunoglobulins,52 highlighting the relevance of correct diagnostic classification.

Although data are largely limited to retrospective series, targeting the underlying clone is feasible in IgM-related neuropathy; the optimum depth of response is unknown. Clinical improvement or stabilization is significantly more likely with rituximab-containing therapy (dexamethasone, rituximab, cyclophosphamide; bendamustine plus rituximab; cyclophosphamide, prednisolone, rituximab, vincristine), non-amyloid-related neuropathy and attainment of at least partial haematologic response.49,50 There is an unmet need for reliable biomarkers for diagnosis, appropriate selection of patients for treatment and criteria for monitoring response.59 There is a lack of prospective clinical trials to optimize treatment options. A phase II clinical trial, MAGNAZ, of the oral BTK inhibitor zanubrutinib in anti-MAG peripheral neuropathies is underway.60

Schnitzler syndrome

Schnitzler syndrome is a rare auto-inflammatory disorder characterized by an IgM monoclonal gammopathy and...
chronic recurrent urticarial rash. The Strasbourg criteria outline additional minor criteria of recurrent fever, abnormal bone remodeling with or without bone pain, neutrophilic dermal infiltrate, leukocytosis and elevated C-reactive protein. Around 300 cases have been reported to date. It is underdiagnosed and, despite its rarity, is important to identify as specific treatment can significantly improve quality of life.

**Clinical characteristics**

Of 281 cases in the largest case series, fever was present in 72%, anemia in 63%, arthralgia in 68%, bone pain in 55%, lymphadenopathy in 26%, and liver or spleen enlargement and neuropathy in less than 10%. In smaller series fatigue and weight loss were documented in up to around 50% of cases. The urticarial rash can cover any part of the body, but face, palm and sole involvement is infrequent, as is in cases. The urticarial rash can cover any part of the body, but face, palm and sole involvement is infrequent, as is in cases. The time from onset of symptoms to diagnosis is long, at a median of 5 years and may be as long as 20 years. The monoclonal gammopathy is almost always IgM. Bone marrow involvement is minimal, being around 4% in one series, and a median M-protein concentration of 6 g/L has been documented. In the largest case series, 63% of the 281 bone marrow samples were reported as normal. The MYD88 L265P mutation was detected in the peripheral blood of 30% of 30 patients. The authors suggested that the presence of this mutation may correlate with the risk of WM, although the mutation detection rate may have been underestimated as the sensitivity of detecting peripheral blood B-cell clones may be hampered when the level of disease burden is low. The frequency of the MYD88 L265P mutation in bone marrow has not been studied. Chronic inflammation may lead to AA amyloidosis in 2% of cases of Schnitzler syndrome. At a median of 8 years, the rate of evolution to lymphoma is 20%, which is in line with progression in unselected cohorts of patients with IgM MGUS. Schnitzler syndrome is associated with cytokine dysregulation. It bears close phenotypic resemblance to an inherited disorder, cryopyrin-associated periodic syndrome, caused by gain-of-function mutations in the NLRP3 gene. This results in upregulation of interleukin (IL)-1β production and has informed therapeutic options in Schnitzler syndrome, by targeting IL-1β.

**Diagnostic workup**

There is no single diagnostic test and the diagnosis is made based on clinical characteristics. Differential diagnoses for the rash and fever include adult-onset Still disease, systemic lupus erythematosus, acquired C1 esterase deficiency, cryopyrinopathies and cryoglobulinemia (cold-induced urticaria). Skin biopsy reveals a neutrophilic urticarial dermatosis without features of vasculitis.

**Treatment**

Treatment is aimed at reducing the considerable morbidity related to rash, fever and joint and bone pain. Symptoms respond poorly to historic first-line agents including antihistamines, nonsteroidal anti-inflammatory drugs, dapsone and colchicine. The use of high-dose steroids, although moderately effective, is limited by long-term toxicities. Without anti-IL treatment, morbidity is high. In a series of 21 patients, all had almost daily symptoms with a profound effect on their quality of life. Anti-IL-1 agents, such as anakinra, canakinumab, and rilonacept, have all been used but not directly compared. Anakinra is the agent with which experience is greatest and is the treatment of choice. It is a recombinant IL-1-receptor antagonist and has the greatest efficacy (94% efficacy in 86 cases), with durable responses (83% complete responses after a median of 36 months). Anakinra has a half-life (t½) of 4-6 hours and provides impressive control of all signs within hours, normalization of C-reactive protein levels and abrogation of the risk of AA amyloidosis. Nonetheless, patients require continuous daily injections and relapse occurs after treatment discontinuation. Canakinumab, an IL-1β monoclonal antibody, is long-acting (t½, 21-28 days) and is, therefore, administered less frequently. Data from phase II, placebo-controlled, randomize trials have demonstrated its efficacy. For 17 patients in a long-term study, clinical efficacy was greatest when patients injected canakinumab as needed. A systematic review of 34 patients showed that 59% achieved complete responses. Rilonacept, an IL-1 binding and neutralizing fusion protein, achieved near complete responses in 50% of cases. To-cilizumab, an IL-6 receptor antagonist, has been beneficial in three patients who were refractory to anakinra. Cyclophosphamide, rituximab and ibrutinib have achieved responses when treatment was given for overt lymphoma but have been largely ineffective or untested in the absence of lymphoma. There is little to support the notion that anti-IL therapy affects the underlying B-cell clone.

**Conclusion**

We have discussed a range of distinctive entities of IgM MGCS, including their specific clinical characteristics, underlying clonal profile, and diagnostic workup as well as treatment considerations. Careful evaluation of the presenting features and thorough interrogation of the underlying clone are critical. Determining the nature of either a mature B-cell derived clone or plasma cell clone will have management implications. There is an IgM predominance in all cases except IgM-associated AL amyloidosis. The indication for treatment is dictated by the
pathological characteristics of the circulating IgM rather than by the tumor itself. While deep suppression of the pathogenic IgM is typically required for response, achieving long-term clonal eradication is challenging, as demonstrated by low complete response rates. Treatment inhibiting the pathogenic effects of IgM while not directed at the underlying clone has led to great success in CAD (complement inhibitors) and Schnitzler syndrome (cytokine inhibition), whereas the other treatments are centered on eradicating the underlying clone. Treatment approaches in cryoglobulinemia and IgM-related peripheral neuropathies are the least well developed. A multidisciplinary approach is required particularly for IgM-related neuropathies and Schnitzler syndrome.

Due to the rarity of IgM MGCS, data are scant and collaborative research is imperative to aid defining optimal treatment strategies. International registries may better define characteristics and assess treatment outcomes. Future work exploring clone-directed treatment options and pathogenic IgM-directed therapies is welcomed.

Disclosures
JK has no conflicts of interest to disclose. SD’S has received research funding, honoraria for advisory board work and conference support from Janssen and BeiGene, and honoraria for advisory board work from Sanofi. MCM has provided speakers bureau services for Medsipe and BMS, consultancy for Janssen-Cilag and Gilead Sciences Netherlands B.V., sat on advisory boards for Janssen Pharamcuitica and Alnylam, and received hospitality support from Celgene. MJK has acted as a consultant for and received honoraria and travel support from Novartis and Miltenyi Biotec, has received research funding from Takeda and Celgene, has acted as a consultant for and received honoraria, travel support and research funding from Kite, a Gilead Company, and Roche, and has acted as a consultant for and received honoraria from BMS/Celgene. AW has provided consultancy services for Alexion, AstroZeneca Rare Diseases and Janssen, and has received honoraria from Celgene and Takeda, clinical trial funding from Caelum Biosciences, and research funding from Amgen. JMIV has received reimbursement of travel costs from Celgene, receives research funding from Beigene (institutional) and has participated in an advisory board as well as acted as a consultant for Sanofi (institutional honoraria)

Contributions
JK and JMIV wrote the first draft of the manuscript, SD’S, MCM, MJK, and AW equally reviewed and added critical discussions throughout the writing of the review.

References

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.

2. Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-1486.

3. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.

4. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinemia. Lancet Haematol. 2020;7(11):e827-e837.

5. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241-249.

6. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9):826-833.

7. Varettoni M, Zibellini S, Defrancesco I, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102(12):2077-2085.

8. Bazazbahchi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021;138(20):1980-1985.

9. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648.

10. Berentsen S, Barcellini W, D’Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136(4):480-488.

11. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460-466.

12. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-2936.

13. Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018;2(19):2543-2549.

14. Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014;99(3):497-504.

15. Malecka A, Trøen G, Delabie J, et al. The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels. Am J Hematol. 2021;96(8):E279-E283.

16. Malecka A, Trøen G, Tierns A, et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol. 2018;183(5):838-842.
26. Kolopp-Sarda MN, Nombel A, Miossec P. Cryoglobulins today: a review. Rheumatology (Oxford). 2005;44(3):410-411.

27. Zhang LL, Cao XX, Shen KN, et al. Clinical characteristics and outcomes of patients with type 1 monoclonal cryoglobulinemia: a study of 64 cases. Br J Haematol. 2015;168(5):671-678.

28. Sidana S, Rajkumar SV, Dispenzieri A, et al. Comparison of type I and type II monoclonal cryoglobulinemia: results of a prospective multicenter trial. Blood. 2017;130(4):537-541.

29. Harel S, Mohr M, Jahn I, et al. Clinico-biological characteristics of chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;138(20):2002-2005.

30. Tomkins O, Berentsen S, Arulogun S, Sekhar M, D’Sa S. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020 Jul 11. doi: 10.1002/ajh.25932. [Epub ahead of print]

31. Röth A, Barcellini W, D’Sa S, et al. Suitimlimab in cold agglutinin disease. N Engl J Med. 2021;384(14):1323-1334.

32. Fattizzo B, Michel M, Zaninoni A, et al. Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. Haematologica. 2021;132(5):622-625.

33. Kolopp-Sarda MN, Nombel A, Miossec P. Cryoglobulins today: detection and immunologic characteristics of 1,675 positive samples from 13,439 patients obtained over six years. Arthritis Rheumatol. 2019;71(11):1904-1912.

34. Zhang LL, Cao XX, Shen KN, et al. Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. Ann Hematol. 2020;99(8):1735-1740.

35. Néel A, Perrin F, Decaux O, et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol. 2014;89(2):156-161.

36. Harel S, Mohr M, Jahn I, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168(5):671-678.

37. Sidana S, Rajkumar SV, Dispenzieri A, et al. Clinical presentation and outcomes of patients with type I monoclonal cryoglobulinemia. Am J Hematol. 2017;92(7):668-673.

38. Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013;92(2):61-68.

39. Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119(25):5996-6004.

40. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinemia. Rheumatology (Oxford). 2005;44(3):410-411.

41. Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60(12):3848-3855.

42. Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood. 2008;112(10):4009-4016.
response in patients with anti-MAG neuropathy: retrospective study. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1109.

54. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10(10):CD002827.

55. Swahn J, Petiot P, Antoine JC, et al. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry. 2018;89(5):499-505.

56. Dalakas MC. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol. 1996;104 (Suppl 1):S5-S60.

57. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123(Pt 4):710-717.

58. Le Cann M, Bouhour F, Viala K, et al. CANOMAD: a neurological monoclonal gamopathy of clinical significance that benefits from B-cell-targeted therapies. Blood. 2020;136(21):2428-2436.

59. Amaador K, Wieske L, Koel-Simmelink MJA, et al. Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J Neurol. 2022;269(7):3700-3705.

60. Minnema MC, Vos J, Eftimov F, Vrancken A. P-034: MAGNAZ trial - a prospective phase II study in patients with monoclonal gamopathy of unknown significance (MGUS) and anti-myelin associated glycoprotein (MAG) neuropathy and zanubrutinib treatment. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 2):S57.

61. Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562-568.

62. Jain T, Offord CP, Kyle RA, Dingli D. Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica. 2013;98(10):1581-1585.

63. de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4:41.

64. Rowczenio DM, Pathak S, Arostegui JI, et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood. 2018;131(9):974-981.

65. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis. 2010;5:38.

66. Pathak S, Rowczenio DM, Owen RG, et al. Exploratory study of MYD88 L265P, rare NLRP3 variants, and clonal hematopoiesis prevalence in patients with Schnitzler syndrome. Arthritis Rheumatol. 2019;71(12):2121-2125.

67. Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev. 2014;13(10):1035-1041.

68. Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in Schnitzler syndrome: a systematic literature review. Semin Arthritis Rheum. 2020;50(4):636-642.

69. Krause K, Weiller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67(7):943-950.

70. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129(3):848-850.

71. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121.

72. Allain JS, Thonier F, Pihan M, et al. IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies. Haematologica. 2018;103(5):e207-e210.

73. Vos JM, Notermans NC, D’Sa S, et al. High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatry. 2018;89(9):1007-1009.

74. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gamopathy of undetermined significance and smoldering Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):17-18.

75. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenström macroglobulinemia: long-term results. Blood. 2012;119(19):4462-4466.

76. Khwaja J, Patel AS, Arulogun SO, et al. IgM paraprotein-associated type 1 cryoglobulinemia: clinical characteristics and outcomes. Blood. 2021;138(Suppl 1):4503-4503.

77. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammapathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383-390.